Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
SPGI$469.39-12.20(-2.53%)Beko's FlexiStart helps households run appliances when electricity is cheaper5:35:00 AM ETAMD$435.00+31.32(+7.76%)Is AMD Stock a Buy After the Spectacular Investor Update?5:30:01 AM ETMETA$608.91+3.24(+0.53%)Meta pauses planned terms updates, keeps existing rules in place5:28:34 AM ETAMD$435.00+31.32(+7.76%)Nvidia, AMD and Intel stocks rebound sharply: is Wall Street's AI panic easing?5:25:39 AM ETBKNG$165.04-3.74(-2.22%)Carnival: Strong Booking Momentum And Discounted Valuation Support A Buy5:21:37 AM ETMU$709.66+52.20(+7.94%)2 Reasons Micron Stock Could Be a Buy Right Now (and 1 Reason for Caution)5:20:00 AM ETGS$872.00+3.77(+0.43%)PRECIOUS-Gold drops, on track for best week in over 2 months before US payrolls5:16:33 AM ETTSLA$350.59+7.27(+2.12%)Tesla to wind down Cybertruck production at Texas factory as it struggles to win appeal5:11:12 AM ETSPCX$129.00+5.61(+4.55%)Could Investing $500 a Month in SpaceX Stock Help You Retire a Millionaire?5:10:00 AM ETRACE$411.73-10.58(-2.51%)Ferrari's Q3 Earnings: Inside The 'Fewer Cars, More Money' Secret5:09:55 AM ETBRK-A$856,700.01-12,600.75(-1.45%)Warren Buffett's Successor, Greg Abel, Has 71% of Berkshire Hathaway's $362 Billion Portfolio Invested in 7 Standout Stocks5:06:02 AM ETMSFT$529.96-5.80(-1.08%)Microsoft's Buyout Offer Sets Its Workforce on Edge5:02:28 AM ETSNOW$278.75+9.43(+3.50%)Why Snowflake's former revenue chief is joining a little-known AI infrastructure startup5:00:03 AM ETGOOG$283.50+1.63(+0.58%)You say you don't want AI. Google's school fight shows what that really means.5:00:02 AM ETNVDA$189.72+8.12(+4.47%)As neoclouds face a financial reckoning, Nvidia has to decide how far to go to help5:00:01 AM ETPLTR$159.08+4.17(+2.69%)Palantir Stock Is Down 19% From Its Highs. Time to Buy the Dip?5:00:00 AM ETMETA$608.91+3.24(+0.53%)Stock-Split Watch: Is Meta Platforms Next?4:49:00 AM ETEQNR$41.91-0.64(-1.50%)Equinor prepares to fix Visund gas, oil platform after fire4:33:34 AM ETTSLA$350.59+7.27(+2.12%)Elon Musk's Net Worth Drops Nearly $80 Billion In A Day As Tesla And SpaceX Stock Crater During Tech Wipe-Out4:27:48 AM ETOSE:EQNR$393.00-12.40(-3.06%)Equinor prepares to fix Visund gas, oil platform after fire4:24:06 AM ETROST$238.15-7.59(-3.09%)Ross Q3 Earnings Preview: Discount Retail Continues To Appeal, Expecting Outperformance4:21:09 AM ETHSBC$86.96-1.13(-1.28%)HSBC HOLDINGS PLC ANNOUNCES INCREASE OF THE MAXIMUM TENDER AMOUNT OF ITS TENDER OFFER FOR ONE SERIES OF SECURITIES4:15:03 AM ETNVDA$189.72+8.12(+4.47%)Should You Buy Nvidia Before Nov. 17? The Evidence is Piling Up and Here's What It Shows.4:05:02 AM ETDELL$342.32+26.52(+8.40%)Smart City Expo 2026 closes after showing the real impact of urban solutions4:00:00 AM ET

NGEN · NASDAQ

NervGen Pharma Corp. Common stock

$1.30 -0.01 (-0.76%)

Company overview

NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$140M
Employees
7
Headquarters
West Vancouver, BC
Website
nervgen.com
CEO
Adam H. Rogers
Listed
February 8, 2021
P/E
-2.01
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$12,213
Operating income
-$32M
EBITDA
-$14.2M
Net income
-$46.7M
EPS
-$0.65
Total assets
$20.8M
Total debt
$0.00
Earnings yield
-49.86%

Price chart

1.171.912.643.374.11
NGEN 1D NASDAQ O1.36H1.39L1.30C1.31-0.04 (-2.96%)Vol316.02K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
NGENNervGen Pharma Corp. Common stock Press release Nature Medicine Publication Reveals How Human Movement Predicts Hidden Biosignals Spanning 18 Body Systems, from Heart and Liver Function to Metabolic and Mental Health GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury GlobeNewswire
NGENNervGen Pharma Corp. Common stock Stock news NervGen Pharma: The Upside Is Large, But Phase 3 Decides Everything Seeking Alpha
NGENNervGen Pharma Corp. Common stock Stock news NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript Seeking Alpha
NGENNervGen Pharma Corp. Common stock Press release NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen to Host Inaugural R&D Day on September 30, 2026 GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire
NGENNervGen Pharma Corp. Common stock Stock news Micron To Rally Around 87%? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga
NGENNervGen Pharma Corp. Common stock Press release NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study GlobeNewswire
DOW Stock news Dow Jumps 250 Points; BJ's Wholesale Shares Fall After Q1 Results Benzinga
NGENNervGen Pharma Corp. Common stock Stock news NervGen Announces Pricing of US$60.0 Million Public Offering of Securities GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Announces Pricing of US$60.0 Million Public Offering of Securities GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Announces Proposed Public Offering of Securities GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia GlobeNewswire
NGENNervGen Pharma Corp. Common stock Press release NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire
NGENNervGen Pharma Corp. Common stock Stock news NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) Seeking Alpha
NGENNervGen Pharma Corp. Common stock Press release NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange GlobeNewswire
See more
FAQ

Questions about NervGen Pharma Corp. Common stock

What does NervGen Pharma Corp. Common stock do?
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
What is NGEN's market cap?
NervGen Pharma Corp. Common stock (NGEN) is a listed stock with a live quote. The latest market cap on this page is $140M.
Where is NervGen Pharma Corp. Common stock headquartered?
NervGen Pharma Corp. Common stock is headquartered in West Vancouver, BC.
How do I get NGEN news from the API?
Call GET /v1/news?tickers=NGEN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does NGEN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for NGEN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the NGEN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs